Cagrilintide

FDA-approved GLP-1 medications and their generic active ingredients.

Definition

Novo Nordisk's long-acting amylin analog. Studied alone (11.5% weight loss at 68 weeks in REDEFINE 1) and as the amylin component of CagriSema combined with semaglutide. Distinct mechanism from GLP-1 agonists — works on amylin receptors that signal satiety via the brainstem.

CagriSema REDEFINE trial results →

Definition curated by Weight Loss Rankings — sourced from FDA labels and peer-reviewed PubMed literature, never AI-generated summaries.

Related terms in Drugs and brands

Wegovy
Ozempic
Rybelsus
Saxenda
Zepbound
Mounjaro
Foundayo
Semaglutide
Tirzepatide
Orforglipron
Retatrutide
CagriSema
Survodutide
MariTide (Maridebart Cafraglutide)
Ecnoglutide

Looking for more depth?

CagriSema REDEFINE trial results
Browse the full GLP-1 glossary (51 terms across 8 categories)
Research articles — primary-source deep dives
Tools and calculators
Compare GLP-1 telehealth providers